Lupin is currently trading at Rs. 1681.50, up by 48.70 points or 2.98% from its previous closing of Rs. 1632.80 on the BSE.
The scrip opened at Rs. 1640.00 and has touched a high and low of Rs. 1684.60 and Rs. 1637.00 respectively. So far 98,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2112.00 on 08-Apr-2015 and a 52 week low of Rs. 903.95 on 27-May-2014.
Last one week high and low of the scrip stood at Rs. 1803.00 and Rs. 1589.40 respectively. The current market cap of the company is Rs. 75,630.00 crore.
The promoters holding in the company stood at 46.63% while Institutions and Non-Institutions held 43.36% and 10.01% respectively.
Lupin has acquired 100% equity stake in Medquímica Indústria Farmacêutica S.A., Brazil, (Medquímica) subject to certain closing conditions. The acquisition marks Lupin’s foray into the high growth Brazilian market and would also shore up its position in the Latin American pharmaceuticals market given the company’s acquisition of Laboratorios Grin in Mexico last fiscal.
Incorporated in 1975, Medquímica is a broad based pharmaceutical company engaged in the development, manufacturing & commercialization of branded generics, pure generics and OTC products. Medquimica is one of the fastest growing companies in the Brazilian branded generics market and a trusted brand with the distribution channel in Brazil.
Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, APIs and biotechnology products.
